Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Lemtrada
|
| gptkbp:activities |
depletes T and B lymphocytes
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:legislation
gptkb:2014 gptkb:United_States |
| gptkbp:associated_with |
risk of secondary malignancies
|
| gptkbp:clinical_trial |
not available
Phase II Phase III first-line therapy for MS second-line therapy for CLL |
| gptkbp:contraindication |
active infections
hypersensitivity to alemtuzumab |
| gptkbp:developed_by |
gptkb:Genzyme
|
| gptkbp:discovered_by |
1990s
|
| gptkbp:dosage_form |
3 days of treatment one year later
5 days of treatment |
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
alemtuzumab
|
| gptkbp:indication |
gptkb:healthcare_organization
B-cell malignancies |
| gptkbp:ingredients |
C6470 H10000 N1714 O2010 S44
|
| gptkbp:invention |
gptkb:2022
|
| gptkbp:is_monitored_by |
infusion reactions
thyroid dysfunction |
| gptkbp:is_used_for |
treatment of multiple sclerosis
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:Lemtrada
|
| gptkbp:operating_hours |
once a year after initial treatment
|
| gptkbp:provides_information_on |
MS treatment guidelines
CLL treatment guidelines |
| gptkbp:research_focus |
gptkb:vaccine
cancer therapy autoimmune diseases transplantation |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea fever rash infections thrombocytopenia lymphopenia autoimmune disorders neutropenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
C D52
|
| gptkbp:weight |
150 k Da
|